Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Core Viewpoint - Quoin Pharmaceuticals is highlighting the urgent need for effective treatments for Netherton Syndrome through the release of a new video featuring a patient advocate, emphasizing the severe impact of the disease on patients' lives and the ongoing development of their lead product candidate, QRX003 [1][5]. Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [7]. - The company is advancing its lead product candidate, QRX003, through multiple pivotal clinical trials aimed at treating Netherton Syndrome [4][5]. Product Information - QRX003 is a topical lotion designed to normalize skin-shedding processes and strengthen the skin barrier, targeting the underlying issues caused by the absence of the LEKTI protein in Netherton patients [6]. - Recent data from ongoing studies of QRX003 have shown highly encouraging improvements in key clinical outcomes [4]. Patient Advocacy and Community Impact - Mandy Aldwin-Easton, featured in the video, shares her personal experiences with Netherton Syndrome, highlighting the chronic pain and emotional trauma associated with the disease [2][3]. - The company recognizes the significant physical, emotional, and financial toll that Netherton Syndrome places on patients and their families, reinforcing the importance of advocacy and awareness [4][5].